Replies to post #401377 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

Aside from any surprises, the next potentially meaningful $AVXL value driving event is the 'expected' H2 2023 EXCELLENCE readout. Potentially filing a NDA or equivalent elsewhere from that readout along with the two adult Rett studies puts any approval into 2024.

I continue to expect that initiation of a likely successful P3 Precision Medicine trial in AD will be the output from the P2b/3 results.